Retinal Neurodegenerative Diseases: Molecular Targets Driving Neuroinflammation and Neuroprotection

Guest Editors:

**Dr. Ana Raquel Santiago**
Coimbra Institute for Clinical and Biomedical Research (iCBR),
Faculty of Medicine, University of Coimbra, Coimbra, Portugal
asantiago@fmed.uc.pt

**Dr. Raquel Boia**
Coimbra Institute for Clinical and Biomedical Research (iCBR),
Faculty of Medicine, University of Coimbra, Portugal
raquel.boia@uc.pt

Deadline for manuscript submissions:
30 November 2021

**Message from the Guest Editors**

Retinal neurodegenerative diseases are among the major causes of blindness worldwide. Glaucoma, diabetic retinopathy, and age-related macular degeneration (AMD) are chronic diseases affecting more than 150 million people worldwide. Despite their different etiologies, chronic neuroinflammation is a common feature that correlates with neurodegeneration. Several cells, like microglia, astrocytes, and immune cells from the periphery and endothelial cells, orchestrate an inflammatory response that drive neurodegeneration. The inflammatory signals occur early and precede neurodegeneration, suggesting that strategies targeting the control of inflammation could provide therapeutic benefits for the treatment of retinal diseases. Several molecular targets and strategies have been proposed to afford protection to the retina, either by acting directly on the affected cells or by controlling inflammation.
The International Journal of Molecular Sciences (IJMS, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. IJMS publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in IJMS and consider publishing your next paper with us.